Bina Innovation Fellowship - Cohort 3 - 7th Session

Bina Fellowship Cohort 3 - Session 7 - Industry experts personal perspectives:

We met three leaders from three domains, each sharing their journey:
Yonatan Cohen (Quantum Machines) - Quantum computing: a platform that orchestrates and controls quantum systems at any scale, bringing advanced capabilities to quantum developers.
David Brocks (Immunai) - AI & Pharma: an AI-driven, end-to-end platform leveraging single-cell multiomics with preclinical and clinical data to map the immune system and generate actionable insights for drug discovery and development.
Raanan Shelach (Carbonade) - Climate Tech: turning CO2 into valuable products using highly efficient electrochemical processes.
We had an open conversation with candid Q&A - about choices, tradeoffs, and navigating uncertainty.

There are many good ideas; it all depends on execution.

Thank you to our experts for their time, their stories, and the insights they shared.

Next up: field trip - to Grove Ventures.

More News

Bina Welcomes Prof. Jakub Abramson as Chair of Bina’s Scientific Committee

Bina is pleased to welcome Prof. Jakub Abramson as Chair of Bina’s Scientific Committee.

Bina Innovation Fellowship - Cohort 3 - 8th Session

Bina Fellowship Cohort 3 - Session 8 - field visit to Grove Ventures.

We had a candid and inspiring conversation with Renana Ashkenazi and Dov Moran, who shared their journeys - successes, setbacks, and the realities behind VC decision-making.
We discussed Grove’s core pillars as well as the questions every founder should ask early on - about the problem, the market, the team, and also about themselves: blind spots, disadvantages, and taking full responsibility.

Thank you to the Grove Ventures team for the openness, generosity, and valuable perspective.

ABC Chat with Eyal Ben Ami - M Ventures

As part of Bina’s ABC meetings, we hosted Dr. Eyal Ben Ami, Associate - Science Lead at M Ventures, the corporate venture capital arm of Merck.
M Ventures invests in early-stage biotech and health-tech companies, sitting right at the intersection of cutting-edge science and global industry.
Eyal took us on a journey from the lab bench to the investor’s chair - from academic research in neuroimmunology, through roles in drug development companies and biotech startups, to his current position as an investor in a corporate VC fund.